These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19566127)

  • 1. On the global dynamics of a model for tumor immunotherapy.
    Kirschner D; Tsygvintsev A
    Math Biosci Eng; 2009 Jul; 6(3):573-83. PubMed ID: 19566127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling immunotherapy of the tumor-immune interaction.
    Kirschner D; Panetta JC
    J Math Biol; 1998 Sep; 37(3):235-52. PubMed ID: 9785481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modeling of the effect of boosting tumor infiltrating lymphocyte in immunotherapy.
    Kartono A; Subiyanto
    Pak J Biol Sci; 2013 Oct; 16(20):1095-103. PubMed ID: 24506008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immunotherapy on the response of TICLs to solid tumour invasion.
    Mambili-Mamboundou H; Sibanda P; Malinzi J
    Math Biosci; 2014 Mar; 249():52-9. PubMed ID: 24480736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?
    Krishchenko AP; Starkov KE
    Math Biosci Eng; 2018 Oct; 15(5):1243-1254. PubMed ID: 30380309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer.
    Bunimovich-Mendrazitsky S; Goltser Y
    Math Biosci Eng; 2011 Apr; 8(2):529-47. PubMed ID: 21631144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal treatment strategy for a tumor model under immune suppression.
    Kim KS; Cho G; Jung IH
    Comput Math Methods Med; 2014; 2014():206287. PubMed ID: 25140193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamical properties and tumor clearance conditions for a nine-dimensional model of bladder cancer immunotherapy.
    Starkov KE; Bunimovich-Mendrazitsky S
    Math Biosci Eng; 2016 Oct; 13(5):1059-1075. PubMed ID: 27775397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the development of immunotherapy for the treatment of patients with cancer.
    Rosenberg SA
    J Intern Med; 2001 Dec; 250(6):462-75. PubMed ID: 11902815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour suppression by immune system through stochastic oscillations.
    Caravagna G; d'Onofrio A; Milazzo P; Barbuti R
    J Theor Biol; 2010 Aug; 265(3):336-45. PubMed ID: 20580640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoring IL-2 to its cancer immunotherapy glory.
    Mullard A
    Nat Rev Drug Discov; 2021 Mar; 20(3):163-165. PubMed ID: 33603157
    [No Abstract]   [Full Text] [Related]  

  • 12. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 therapy: a decade of slow but steady progress.
    Atkins MB
    Cancer J Sci Am; 1996; 2(2):73-5. PubMed ID: 9166502
    [No Abstract]   [Full Text] [Related]  

  • 14. Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.
    Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
    J R Soc Interface; 2017 Jun; 14(131):. PubMed ID: 28659410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4
    Wei HC; Yu JL; Hsu CY
    Comput Math Methods Med; 2017; 2017():2906282. PubMed ID: 29250133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.
    Kim S; Haas GP; Hillman GG
    Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico tumor control induced via alternating immunostimulating and immunosuppressive phases.
    Reppas AI; Alfonso JC; Hatzikirou H
    Virulence; 2016; 7(2):174-86. PubMed ID: 26305801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
    Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z
    Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 and interleukin-15: immunotherapy for cancer.
    Fehniger TA; Cooper MA; Caligiuri MA
    Cytokine Growth Factor Rev; 2002 Apr; 13(2):169-83. PubMed ID: 11900992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of tumour-immune evasion with chemo-immuno therapeutic treatment with quadratic optimal control.
    Ravindran NS; Sheriff MM; Krishnapriya P
    J Biol Dyn; 2017 Dec; 11(1):480-503. PubMed ID: 28976297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.